MaxCyte Pe Ratio from 2010 to 2025

MXCT Stock  USD 3.09  0.02  0.65%   
MaxCyte PE Ratio yearly trend continues to be comparatively stable with very little volatility. PE Ratio will likely drop to -11.16 in 2025. From the period from 2010 to 2025, MaxCyte PE Ratio quarterly data regression had r-value of  0.80 and coefficient of variation of (105.33). View All Fundamentals
 
PE Ratio  
First Reported
2010-12-31
Previous Quarter
(10.62)
Current Value
(11.16)
Quarterly Volatility
225.41829413
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5 M, Interest Expense of 138.6 K or Selling General Administrative of 31.2 M, as well as many indicators such as Price To Sales Ratio of 10.73, Dividend Yield of 0.0 or PTB Ratio of 2.22. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
  
Check out the analysis of MaxCyte Correlation against competitors.
For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.

Latest MaxCyte's Pe Ratio Growth Pattern

Below is the plot of the Pe Ratio of MaxCyte over the last few years. It is MaxCyte's PE Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
Pe Ratio10 Years Trend
Slightly volatile
   Pe Ratio   
       Timeline  

MaxCyte Pe Ratio Regression Statistics

Arithmetic Mean(214.01)
Geometric Mean102.40
Coefficient Of Variation(105.33)
Mean Deviation189.46
Median(93.41)
Standard Deviation225.42
Sample Variance50,813
Range761
R-Value0.80
Mean Square Error20,009
R-Squared0.63
Significance0.0002
Slope37.65
Total Sum of Squares762,201

MaxCyte Pe Ratio History

2025 -11.16
2024 -10.62
2023 -12.8
2022 -28.07
2021 -45.88
2020 -93.41
2019 -70.62

About MaxCyte Financial Statements

MaxCyte shareholders use historical fundamental indicators, such as Pe Ratio, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
PE Ratio(10.62)(11.16)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.